John Amory
Corporate Officer/Principal chez University of Washington
Profil
John A.
Amory is a Professor at the University of Washington, where he has been working since 2011.
He previously worked as a Director at Clarus Therapeutics, Inc. and as an Independent Director at Clarus Therapeutics Holdings, Inc. from 2021 to 2022.
Amory received a graduate degree from the University of Washington and a doctorate from the University of California, San Francisco.
Postes actifs de John Amory
| Sociétés | Poste | Début |
|---|---|---|
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | 01/07/2011 |
Anciens postes connus de John Amory
| Sociétés | Poste | Fin |
|---|---|---|
| CLARUS THERAPEUTICS HOLDINGS, INC. | Director/Board Member | 31/10/2022 |
Clarus Therapeutics, Inc.
 Clarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Clarus Therapeutics, Inc. operated as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy. It offered JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company was founded by Robert E. Dudley in February 2004 and was headquartered in Northbrook, IL. | Director/Board Member | - |
Formation de John Amory
| University of Washington | Graduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CLARUS THERAPEUTICS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Clarus Therapeutics, Inc.
Clarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Clarus Therapeutics, Inc. operated as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy. It offered JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company was founded by Robert E. Dudley in February 2004 and was headquartered in Northbrook, IL. | Health Technology |
